AZD7442_PROVENT GRAPHICAL ABSTRACT.pdf (172.93 kB)
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials
Version 2 2024-05-07, 09:19
Version 1 2024-05-03, 13:52
media
posted on 2024-05-07, 09:19 authored by Adis Rapid Journals on behalf of:, Myron J. Levin, Andrew Ustianowski, Stephane de Wit, Rohini Beavon, Jesse Thissen, Seth Seegobin, Kanika Dey, Karen A Near, Katie Streicher, Alexandre Kiazand, Mark T. EsserThe above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).
